0%

est. 2Y upside i

HealthcareSeries D+

Rank

#2079

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Data is insufficient to compute equity upside.

Last updated: July 19, 2026

Bull (20%)0%

If clinical adoption accelerates, valuation could double, but without revenue data, upside cannot be quantified.

Base (55%)0%

Expected path unclear; key financial metrics missing.

Bear (25%)-100%

If product fails to gain traction, common stock could be worthless given $250M preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

0%

Total preferred stock funding is $250M, with no disclosed valuation, implying a potentially large liquidation preference overhang.

Dilution Risk

high

Further raises are likely given post-revenue commercialization costs and no path to cash flow break-even.

Secondary Liquidity

none

No secondary market data available; shares likely illiquid until exit.

Questions to Ask at the Interview

Strategic questions based on Inflammatix's data — designed to show you've done your homework.

  • 1

    “What is the company's current run-rate revenue and gross margin profile?”

  • 2

    “How many TriVerity tests were sold in the first six months post-FDA clearance?”

  • 3

    “What is the expected timeline to profitability and how does equity dilution factor in?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.